MedTrace Logo

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03657797 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 656

Last updated 2023-06-18

Study results available
· View outcomes & findings →

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.

Conditions

  • Glaucoma, Open-Angle
  • Hypertension, Ocular

Interventions

DRUG

NCX 470

NCX 470 Ophthalmic Solution

DRUG

Latanoprost 0.005%

Latanoprost 0.005% Ophthalmic Solution

Sponsors & Collaborators

  • Nicox Ophthalmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicox Ophthalmics, Inc. · Nicox Ophthalmics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-08-23
Completion
2019-08-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657797 on ClinicalTrials.gov